BridgeBio
BBIO
$68.39
-5.51%
BridgeBio Pharma is a commercial-stage biotechnology company focused on discovering, developing, and delivering transformative treatments for patients with genetic diseases, with a late-stage pipeline spanning Mendelian disorders, oncology, and gene therapy. Its flagship commercial asset, Attruby (acoramidis), is an orally administered transthyretin stabilizer approved for transthyretin amyloid cardiomyopathy (ATTR-CM), positioning the company as a direct competitor to Pfizer's tafamidis franchise and Alnylam's RNAi-based therapies in a multi-billion-dollar cardiology market. The investor narrative has shifted decisively from pipeline speculation to commercial execution, with Attruby launch metrics, payer coverage, and the company's path to profitability now the central debate; recent headlines highlight strong Attruby sales, promising Phase 3 achondroplasia (dwarfism) data with an FDA filing planned for 2026, and analyst enthusiasm tempered by persistent GAAP losses. With a market capitalization near $15 billion and only 839 employees, BridgeBio is a high-leverage, catalyst-driven story where clinical and regulatory milestones can move the stock violently in either direction.…
BBIO
BridgeBio
$68.39
Related headlines
Investment Opinion: Should I buy BBIO Today?
The synthesized recommendation is Hold. BridgeBio presents a compelling commercial growth story with Attruby, but the current valuation of 30.05x trailing sales already embeds aggressive assumptions about future profitability, and the company remains deeply unprofitable with negative free cash flow. The analyst consensus of strong buy (1.5 mean) and average target of $109.10 imply 50.6% upside, but the wide target range ($80-$157) and recent 13.60% one-month decline suggest high uncertainty and potential for further volatility.
The supporting evidence for a Hold is balanced: revenue growth of 66.78% year-over-year is exceptional, gross margins of 94.64% are best-in-class, and the cash position of $882.0 million provides runway. However, the net loss of -$164.0 million in Q1 2026, negative operating cash flow of -$197.3 million, and negative equity (debt-to-equity of -1.31) highlight the financial fragility. The forward PE of 2,637x reflects a near-zero forward earnings base, and the PS ratio of 30.05x is 275-500% above the sector average, leaving little room for execution missteps. The implied upside to the average target is attractive, but the risk/reward is skewed by the premium valuation and the need for flawless execution.
The biggest risks that could invalidate the thesis are: (1) Attruby revenue growth decelerating below 20% sequentially, which would challenge the premium multiple; (2) a delay or failure in the achondroplasia FDA filing, removing a key pipeline catalyst; and (3) continued cash burn forcing dilutive equity issuance. The rating would upgrade to Buy if the PS ratio compresses below 20x while revenue growth remains above 50%, or if the company demonstrates a clear path to positive operating cash flow within four quarters. It would downgrade to Sell if revenue growth falls below 30% year-over-year or if the cash balance drops below $500 million without a financing plan. Relative to its own history, the 30.05x PS is near the low end of its historical band, but relative to peers, the stock is significantly overvalued, making it fairly valued at best for risk-tolerant investors.
Sign up to view all
BBIO 12-Month Price Forecast
BridgeBio is a high-risk, high-reward commercial-stage biotech with a promising but unproven path to profitability. The Attruby launch is exceeding expectations, but the valuation already reflects a successful ramp, and the company's cash burn and negative equity leave little room for error. The analyst consensus is bullish, but the recent price weakness and wide target spread suggest the market is pricing in significant uncertainty. I would upgrade to bullish if Q2 2026 revenue exceeds $220 million and operating cash flow improves sequentially, or if the achondroplasia filing is accepted with a priority review. I would downgrade to bearish if revenue growth decelerates below 20% sequentially or if the company announces a large equity raise at a discount.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BridgeBio's 12-month outlook, with a consensus price target around $109.10 and implied upside of +59.5% versus the current price.
Average Target
$109.10
0 analysts
Implied Upside
+59.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$80 - $157
Analyst target range
BridgeBio is covered by 21 analysts, and the consensus recommendation is a strong buy with a recommendation mean of 1.5 (where 1.0 is a strong buy and 5.0 is a sell). The average price target is $109.10, which implies approximately 50.6% upside from the current price of $72.44, and the consensus is decisively bullish, with the target sitting well above the 52-week high of $93.42. This level of optimism reflects analyst confidence in Attruby's commercial trajectory, the achondroplasia Phase 3 data and planned 2026 FDA filing, and the broader pipeline, though the recent 13.60% one-month decline has widened the gap between price and target, suggesting either a compelling entry point or a sign that the market is discounting risks the sell-side has not yet fully incorporated.
The target range spans from a low of $80.00 to a high of $157.00, a spread of $77.00, or roughly 96% of the low target, which signals meaningful disagreement about the company's future. The high target of $157.00 implies roughly 117% upside and likely assumes aggressive Attruby market-share gains, successful pipeline readouts, and a rapid path to profitability that justifies a premium multiple on peak sales. The low target of $80.00 still represents about 10.4% upside from the current price, suggesting even the most cautious analyst sees limited downside, but it likely prices in slower commercial uptake, competitive pressure from Alnylam and Pfizer, and continued cash burn. Institutional ratings show a stable-to-mixed pattern: HC Wainwright has repeatedly reiterated Buy, Mizuho and Morgan Stanley maintain Outperform/Overweight, but Raymond James downgraded to Market Perform from Outperform on May 26, 2026, a notable cautionary signal. The wide target spread combined with the recent price weakness indicates high uncertainty, and investors should weigh the strong consensus against the risk that the market is already looking past the current catalyst cycle.
Bulls vs Bears: BBIO Investment Factors
The bull case rests on Attruby's explosive revenue ramp (66.78% YoY growth to $194.5 million in Q1 2026), exceptional 94.64% gross margins, and a strong analyst consensus with 50.6% upside to the $109.10 average target. The bear case centers on the company's deep unprofitability (-$164.0 million net loss in Q1 2026), negative free cash flow (-$454.1 million TTM), a 30.05x PS ratio that is 275-500% above sector norms, and negative equity. Currently, the bear evidence carries more weight because the valuation already prices in a successful commercial ramp and profitability inflection, leaving little margin for error; the recent 13.60% one-month decline and 12.54 percentage point underperformance versus the S&P 500 suggest the market is beginning to question the timeline. The single most important tension is whether Attruby revenue can scale fast enough to close the cash burn gap before the company needs to raise dilutive capital or take on more debt. If Q2 2026 revenue exceeds $220 million and operating expenses stabilize, the bull case regains momentum; if growth decelerates below 20% sequentially, the premium multiple could compress sharply.
Bullish
- Attruby revenue ramp is explosive: Q1 2026 revenue reached $194.5 million, up 66.78% year-over-year from $116.6 million in Q1 2025 and up 26.1% sequentially from $154.2 million in Q4 2025. The five-quarter climb from just $5.9 million in Q4 2024 to $194.5 million represents roughly a 33x increase, validating the commercial thesis for the ATTR-CM franchise.
- Exceptional gross margin and operating leverage: Gross margin stands at 94.64% (gross profit of $184.1 million on $194.5 million revenue), well above the typical large-cap biotech range. As revenue scales, this high incremental margin should drive rapid operating leverage, with the net loss already narrowing from -$197.2 million in Q4 2025 to -$164.0 million in Q1 2026.
- Strong analyst consensus with 50.6% upside: 21 analysts rate BBIO a strong buy (recommendation mean 1.5), with an average price target of $109.10 implying 50.6% upside from the current $72.44. The low target of $80.00 still offers 10.4% upside, suggesting even the most cautious analyst sees limited downside.
- Pipeline catalyst: achondroplasia FDA filing: Positive Phase 3 data in achondroplasia (dwarfism) positions BridgeBio for an FDA filing in 2026, potentially adding a second commercial asset in a market where BioMarin's Voxzogo faces new competition. This pipeline optionality is not yet reflected in current product revenue.
Bearish
- Deeply unprofitable with heavy cash burn: Q1 2026 net loss was -$164.0 million on a -145.3% net margin, with operating expenses of $290.0 million overwhelming gross profit. Trailing-twelve-month free cash flow is -$454.1 million, and Q1 operating cash flow was -$197.3 million, meaning the business consumes cash faster than it generates it.
- Extreme valuation premium to sector: The trailing PS ratio of 30.05x and EV/Sales of 23.61x represent a 275-500% premium to the typical large-cap biotech average of 5-8x sales. This premium prices in aggressive assumptions about Attruby peak sales and a rapid path to profitability that has yet to materialize.
- Negative equity and high leverage: The debt-to-equity ratio of -1.31 and negative book value (P/B of -7.27) reflect a capital structure where liabilities exceed equity. Quarterly interest expense of $52.8 million consumes a significant portion of gross profit, and the company remains dependent on external financing.
- Recent momentum breakdown and underperformance: The stock is down 13.60% over the past month versus a 1.06% decline in the S&P 500, a relative underperformance of 12.54 percentage points. The 20.25% maximum drawdown from peak and mid-range positioning (52.8% of 52-week range) signal deteriorating momentum that could persist without a catalyst.
BBIO Technical Analysis
BBIO is in a broad recovery uptrend that has cooled considerably in recent months, with the shares up 37.72% over the trailing year but down 7.41% year-to-date. At a current price of $72.44, the stock sits at roughly 52.8% of its 52-week range (52-week low of $48.78, 52-week high of $93.415), meaning it has surrendered a large portion of its earlier gains and is now trading in the middle of its annual band rather than near highs. This mid-range positioning signals neither momentum-chasing territory nor deep-value capitulation; instead, it reflects a market that has repriced the stock lower after a powerful run, leaving it vulnerable to further mean reversion if near-term catalysts disappoint. The 20.25% maximum drawdown from peak confirms that the prior uptrend has been decisively interrupted, and the burden of proof now rests on fundamental execution to re-establish the highs.
Short-term momentum has deteriorated sharply and is diverging bearishly from the longer-term trend. The stock is down 13.60% over the past month versus a 1-year gain of 37.72%, and its 1-month relative strength versus the S&P 500 is -12.54 percentage points (SPY -1.06% over the same period), indicating severe underperformance. The 3-month change of +8.44% and 6-month change of +4.37% show that the bulk of the rally occurred earlier in the year, with the July spike to $90.17 (on July 9) marking the momentum peak before a steady grind lower through August and September. The 1-month decline against a positive 3-month and 1-year backdrop is a classic deceleration pattern that often precedes either a base-building consolidation or a deeper trend reversal, and the lack of volume confirmation (recent volume of ~1.77 million shares) suggests no aggressive accumulation is offsetting the selling pressure.
Key technical levels are well defined: support rests at the 52-week low of $48.78, roughly 32.7% below the current price, while resistance sits at the 52-week high of $93.415, about 29.0% above. A breakout above $93.42 would signal a resumption of the primary uptrend and likely require a fundamental catalyst such as strong Attruby revenue or an FDA filing update, whereas a breakdown below $48.78 would confirm a full trend reversal and could trigger momentum-driven selling. With a beta of 0.971, BBIO is roughly as volatile as the broader market on a statistical basis, but this understates its event-driven risk profile; biotech catalysts can produce single-day moves far exceeding what beta implies, so position sizing should account for gap risk around clinical and regulatory news rather than relying on beta alone.
Beta
0.97
0.97x market volatility
Max Drawdown
-24.1%
Largest decline past year
52-Week Range
$49-$93
Price range past year
Annual Return
+32.9%
Cumulative gain past year
| Period | BBIO Return | S&P 500 |
|---|---|---|
| 1m | -14.4% | -2.4% |
| 3m | +1.5% | +2.2% |
| 6m | -2.4% | +14.8% |
| 1y | +32.9% | +14.6% |
| ytd | -12.6% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BBIO Fundamental Analysis
BridgeBio's revenue trajectory has inflected dramatically upward, driven by the Attruby launch. Q1 2026 revenue reached $194.5 million, representing 66.78% year-over-year growth versus Q1 2025's $116.6 million, and the sequential progression from Q4 2025's $154.2 million confirms accelerating commercial momentum. The revenue mix is overwhelmingly product-driven, with $180.6 million from product sales, $9.5 million from royalties, and $4.4 million from license and service revenue, underscoring that Attruby is now the engine of the entire story. The multi-quarter trend is unambiguous: revenue has climbed from just $5.9 million in Q4 2024 to $120.7 million in Q3 2025, $154.2 million in Q4 2025, and $194.5 million in Q1 2026, a roughly 33x increase in five quarters that validates the commercial thesis but also raises the bar for future comparisons.
Profitability remains the central concern despite the revenue ramp. Q1 2026 net income was -$164.0 million on a gross margin of 94.64% (gross profit of $184.1 million), with operating income of -$106.0 million and an operating margin of -54.47%. The gross margin is exceptionally strong and typical of a successful branded pharmaceutical, but it is being overwhelmed by operating expenses of $290.0 million, including $126.6 million in R&D and $163.9 million in SG&A, plus $52.8 million in quarterly interest expense. The net loss has narrowed from -$197.2 million in Q4 2025 and -$182.7 million in Q3 2025, but the company remains deeply unprofitable on a GAAP basis, and the -145.3% net margin reflects the heavy fixed-cost structure required to commercialize Attruby and advance the pipeline.
The balance sheet shows a company funding its losses through a mix of cash and external capital. Free cash flow is deeply negative at -$454.1 million on a trailing-twelve-month basis, and Q1 2026 operating cash flow was -$197.3 million, meaning the business is consuming cash faster than it generates it. Liquidity is adequate for now, with $882.0 million in cash at the end of Q1 2026 and a current ratio of 2.62, but the debt-to-equity ratio of -1.31 and negative book value (P/B of -7.27) reflect a capital structure where liabilities exceed equity, and the company issued $28.1 million in common stock and drew $549.9 million in net financing during the quarter while repaying $608.4 million of debt. The -25.997% ROA and the negative FCF yield signal that BridgeBio remains dependent on external financing to fund its growth, and while the cash position provides runway, continued losses will eventually force further dilution or debt issuance unless Attruby revenue scales fast enough to close the gap.
Quarterly Revenue
$194515000.0B
2026-03
Revenue YoY Growth
+66.8%
YoY Comparison
Gross Margin
94.6%
Latest Quarter
Free Cash Flow
$-454120000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BBIO Overvalued?
Because BridgeBio's trailing net income is negative (-$164.0 million in Q1 2026, with trailing EPS of -$0.048), the PE ratio is not meaningful and I have selected the price-to-sales (PS) ratio as the primary valuation metric, supplemented by EV/Sales. The trailing PS ratio stands at 30.05x and EV/Sales at 23.61x, while the forward PE of 2,637x is technically positive but reflects a near-zero forward earnings base rather than a meaningful multiple. The enormous gap between the trailing PS of 30.05x and the forward earnings-based valuation implies the market is pricing in a dramatic profitability inflection, with consensus estimated EPS of $10.34 and estimated revenue of $4.72 billion, which would represent roughly a 24x increase from current quarterly revenue run-rates.
Relative to the biotechnology sector, BridgeBio's 30.05x PS ratio is a substantial premium to the typical large-cap biotech average of roughly 5-8x sales, implying a premium of 275-500% depending on the peer set. This premium is partially justified by the 66.78% year-over-year revenue growth and the 94.64% gross margin, which are well above sector norms, but it also reflects the market's aggressive assumptions about Attruby's peak sales potential and pipeline optionality. The negative EV/EBITDA of -25.63x and negative P/B of -7.27x are artifacts of the company's unprofitable status and negative equity, and they underscore that traditional value metrics are inapplicable here; the valuation is entirely a function of future cash flows that have yet to materialize.
Historically, BridgeBio's PS ratio has been extraordinarily volatile, ranging from 18.06x in Q2 2022 to 4,350.60x in Q3 2022 and 883.74x in Q4 2024, as revenue was negligible before the Attruby launch. The current 30.05x PS is near the low end of the company's own historical band, which is a direct consequence of revenue finally scaling, but it remains far above the sector average. This suggests the market has already priced in a successful commercial ramp and is now waiting for evidence that profitability will follow; if Attruby sales continue to compound and operating leverage materializes, the multiple could compress through earnings growth rather than price declines, but any slowdown in the launch would leave the stock exposed to a sharp de-rating given the premium embedded in the current valuation.
PE
-20.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-25.6x
Enterprise Value Multiple
Investment Risk Disclosure
BridgeBio's financial risk profile is dominated by its cash burn and negative equity. Q1 2026 operating cash flow was -$197.3 million, and trailing-twelve-month free cash flow is -$454.1 million, meaning the company is consuming cash at a rate that could exhaust its $882.0 million cash balance within roughly two years if not for external financing. The debt-to-equity ratio of -1.31 and negative book value (P/B of -7.27) indicate that liabilities exceed assets, and quarterly interest expense of $52.8 million consumes a meaningful portion of the $184.1 million gross profit. While the current ratio of 2.62 provides short-term liquidity, the company's reliance on capital markets—evidenced by $549.9 million in net financing drawn in Q1 2026—exposes it to dilution risk if equity markets tighten or sentiment toward unprofitable biotech deteriorates.
Market and competitive risks are substantial given the premium valuation and competitive landscape. The stock trades at 30.05x trailing sales, a 275-500% premium to the 5-8x sector average, leaving it vulnerable to multiple compression if growth slows or profitability is delayed. Attruby competes directly with Pfizer's tafamidis franchise and Alnylam's RNAi therapies in the ATTR-CM market, and any market share erosion or pricing pressure could undermine the revenue trajectory. The beta of 0.971 suggests BBIO moves roughly in line with the broader market, but this understates event-driven risk; clinical trial failures, regulatory setbacks, or competitive data readouts can cause single-day moves far exceeding what beta implies. Recent news highlights BioMarin's royalty deal with Ascendis to offset Voxzogo competition, a reminder that the achondroplasia market is becoming more crowded, which could limit the commercial opportunity for BridgeBio's pipeline candidate.
In a worst-case scenario, a combination of slowing Attruby sales, a delay or rejection of the achondroplasia FDA filing, and a broader biotech selloff could drive the stock toward its 52-week low of $48.78, representing a 32.7% decline from the current price of $72.44. If the company also needs to raise equity at depressed prices to fund operations, dilution could compound the losses. The analyst low target of $80.00 implies only 10.4% upside, but in a severe downturn, the stock could overshoot to the downside, potentially testing the $48.78 low or lower if cash burn accelerates and financing becomes unavailable. Investors should be prepared for a drawdown of 30-35% from current levels in this adverse scenario, with the possibility of further downside if pipeline catalysts fail.
FAQ
The most severe risk is financial: BBIO is deeply unprofitable with a -$164.0 million net loss in Q1 2026 and -$454.1 million trailing free cash flow, and its debt-to-equity ratio of -1.31 and negative book value indicate a fragile balance sheet. Second, competitive risk is high, as Attruby faces Pfizer's tafamidis and Alnylam's RNAi therapies in the ATTR-CM market, and any market share loss could undermine the growth story. Third, valuation risk is significant, with a 30.05x PS ratio that is 275-500% above sector averages, leaving the stock vulnerable to multiple compression if growth decelerates. Fourth, pipeline risk: the achondroplasia program is a key catalyst, and an FDA delay or rejection would remove a major source of upside. Finally, macro risk: as a biotech with a beta of 0.971, BBIO is sensitive to interest rate changes and sector rotation, and a risk-off environment could disproportionately impact unprofitable growth stocks.
Our 12-month forecast assigns a 50% probability to a base case target range of $95-$115, a 25% probability to a bull case of $130-$157, and a 25% probability to a bear case of $48-$80. The base case assumes Attruby revenue grows steadily to an annualized $800 million by mid-2027, with the net loss narrowing but GAAP profitability still elusive. The bull case requires Attruby to exceed $1 billion annualized and the achondroplasia program to gain FDA approval, driving the stock toward the analyst high target of $157. The bear case is triggered by slowing revenue growth, a regulatory setback, or a dilutive financing, pushing the stock toward the 52-week low of $48.78. The most likely scenario is the base case, with the key assumption being sustained 15-20% sequential revenue growth and no major competitive disruptions.
BBIO appears overvalued on traditional metrics, with a trailing PS ratio of 30.05x and EV/Sales of 23.61x, compared to the large-cap biotech average of 5-8x sales. The forward PE of 2,637x reflects a near-zero forward earnings base, and the negative P/B of -7.27x and EV/EBITDA of -25.63x are artifacts of unprofitability. However, the premium is partially justified by 66.78% year-over-year revenue growth and a 94.64% gross margin, which are well above sector norms. The market is pricing in a successful Attruby ramp and a rapid path to profitability; if those expectations are met, the multiple could compress through earnings growth rather than price declines. Relative to its own history, the 30.05x PS is near the low end of its historical band, but relative to peers, it is significantly overvalued.
BBIO is a high-risk, high-reward biotech that may be a good buy for investors with a high risk tolerance and a long-term horizon, but it is not suitable for conservative portfolios. The stock trades at $72.44, with analysts projecting an average target of $109.10 (50.6% upside), but the company remains unprofitable with a net loss of -$164.0 million in Q1 2026 and negative free cash flow of -$454.1 million TTM. The biggest downside risk is a retest of the 52-week low of $48.78, representing a 32.7% decline, if Attruby growth slows or pipeline catalysts fail. For those who believe in the Attruby commercial story and can tolerate volatility, the risk/reward may be favorable, but position sizing should be conservative given the binary nature of biotech catalysts.
BBIO is better suited for long-term investors who can tolerate volatility and hold through clinical and regulatory catalysts, with a suggested minimum holding period of 2-3 years to allow Attruby to scale and the pipeline to mature. The stock has a beta of 0.971, but its event-driven nature means single-day moves can be extreme, making it inappropriate for short-term trading unless one has a high risk tolerance and active monitoring capability. The company pays no dividend (payout ratio 0), so returns depend entirely on capital appreciation. Earnings visibility is low due to the early commercial stage and pipeline binary events, so investors should be prepared for significant drawdowns, such as the 20.25% maximum drawdown observed in the past year. For those with a shorter horizon, the stock may be too volatile, and a wait-and-see approach until profitability is in sight could be prudent.